SAVA Stock Price: Cassava Sciences Inc. drops after record-setting day from analyst upgrade

NASDAQ:SAVA fell nearly 10% on Tuesday following a near 90% rise to start the week.
Analyst upgrades followed after Cassava’s positive announcement regarding its Alzheimer’s clinical trials.

Stocks Reporter FXStreet

NASDAQ:SAVA pulled back on Tuesday after nearly doubling in price on Monday after Wall Street analysts were bullish on the biotech’s results from a Phase 2B clinical trial of their Alzheimer’s treatment Sumifilam. Shares fell 9.42% to close Tuesday’s trading session at $7.02 which is still well above its 50-day and 200-day moving averages. This comes after the stock skyrocketed by over 145% on Monday following the Cassava’s announcement. Trading volume has been high the last couple of days with over 14 million shares being traded on Tuesday compared to the average trading volume of 4 million.

Sumifilam showed a response rate of patients who showed improvements of 98% which is wonderful news for the company after news in May came out that the trial failed to achieve its primary endpoints. The reversal in the treatment’s performance was music to investors' ears as the micro-cap biotech company based out of Austin, Texas nearly doubled its market cap in the span of 24 hours. Maxim analyst Jason McCarthy upgraded his stance to buy and hold and eagerly announced a new long-term price target of $14. McCarthy used 2025 as the key year in which the finalized drug approval and potential launch would happen so investors do have a bit of a longer-term horizon if McCarthy is accurate in his claims.

SAVA stock forecast

In the short-term, SAVA may have already accomplished a bulk of its growth over the last couple of days. Cassava hopes to have Phase 3 trials for Sumifilam to begin by late 2021 and is set to last a few years so McCarthy’s time estimates may be spot on. Investors should be in it for the long haul now as a successful Phase 3 could run the stock price up again and establish Cassava as a leader in the field of Alzheimer’s treatments.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

GBP/USD flirts with two-day lows near 1.3180

GBP/USD remains on the back foot in the latter part of Tuesday’s session, sliding to the sub-1.3200 area and challenging weekly lows. Cable’s decline comes as investors assess the political uncertainty in the UK, coupled with softer-than-expected UK PMI data and the better tone in the Greenback.

EUR/USD weakens below 1.1400 on stronger Dollar

EUR/USD adds to Monday’s losses and recedes below the 1.1400 support to clinch fresh 13-month lows in the latter part of Tuesday’s NA session. The pair’s marked sell-off comes on the back of the persistent move higher in th US Dollar, always propped up by rising bets of further tightening by the Fed.

Gold loses ground to near $4,100 as inflation concerns, Fed rate hike bets build

Gold price loses momentum to around $4,100 during the early Asian session on Wednesday. The precious metal extends the decline as traders cement views on the US Federal Reserve hiking interest rates this year.

Australia CPI set to show inflation accelerated again in May

The Australian Bureau of Statistics will publish the high-impact Consumer Price Index for May on Wednesday at 01:30 GMT. Heading into the inflation test, the Australian Dollar is at its lowest level in two months against the US Dollar, having surrendered the 0.7000 psychological mark.

"Rearranging the deckchairs on the Titanic": UK's fiscal crisis outlasts another Prime Minister

Keir Starmer's resignation as the UK Prime Minister comes ten years after the Brexit referendum vote, a coincidence that financial markets have been quick to note. The British Pound trades around 1.3220 against the US Dollar on Thursday.

Regime change: Inside Kevin Warsh's first move to make the Fed unreadable on purpose

The rate did not move. That was the least interesting thing about Kevin Warsh's first meeting in charge of the Fed. The FOMC held its benchmark at 3.50%-3.75% for the fourth straight meeting, exactly as priced, and then the new chair used his first press conference to dismantle the machinery the market has leaned on for a decade.